Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Information Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,773 |
Ending reported balance
After 2026-10-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 1,607 · Balance 41,401 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 1,084 · Balance 42,485 Row 3 · 2026-10-01 · Exercise / conversion · Acquired 1,995 · Balance 44,480 Row 4 · 2026-10-01 · Exercise / conversion · Acquired 1,360 · Balance 45,840 Row 5 · 2026-10-01 · Tax withholding · Disposed 3,067 · Balance 42,773 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-01 · Exercise / conversion · Disposed 1,607 · Balance 0 F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 1,084 · Balance 0 F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,978 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 1,995 · Balance 7,978 F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,162 |
Reported balance
After 2026-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-01 · Exercise / conversion · Disposed 1,360 · Balance 8,162 F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2022 Filed Sep 13, 2022 20:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 3,245 | $59.28 | $192,363.60 |
DisclosureSEC source: 0001576280-22-000079 · wf-form4_166310002869043.xml · nonDerivative · entry 4 Kalia Kumud · CIK 0001927831 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,260 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 6,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000079 · wf-form4_166310002869043.xml · nonDerivative · entry 3 Kalia Kumud · CIK 0001927831 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2022 Filed Sep 13, 2022 20:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 2,840 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000079 · wf-form4_166310002869043.xml · derivative · entry 5 Kalia Kumud · CIK 0001927831 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,523 Underlying: COMMON STOCK · 2,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on September 1, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each quarterly anniversary of September 1, 2022, during the three-year period thereafter. F3 · derivative.expiration_date: Not applicable to Restricted Stock Units. Read SEC document |
| September 01, 2022 Filed Sep 13, 2022 20:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 1,409 | $49.07 | $69,139.63 |
DisclosureSEC source: 0001576280-22-000079 · wf-form4_166310002869043.xml · nonDerivative · entry 2 Kalia Kumud · CIK 0001927831 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,961 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 01, 2022 Filed Sep 13, 2022 20:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000079 · wf-form4_166310002869043.xml · nonDerivative · entry 1 Kalia Kumud · CIK 0001927831 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,000 | $51.39 | $102,781.00 |
DisclosureSEC source: 0001576280-22-000071 · wf-form4_166094049005607.xml · nonDerivative · entry 1 Kalia Kumud · CIK 0001927831 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,530 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $51.3812 to $51.395, inclusive. The Reporting Persons undertake to provide to theIssuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.